<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060523</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-42</org_study_id>
    <nct_id>NCT05060523</nct_id>
  </id_info>
  <brief_title>To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)</brief_title>
  <official_title>To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial) - An Open Label Placebo Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized controlled trial , The patients who satisfy the below inclusion and&#xD;
      exclusion criteria will be included and they will be randomised, according to 2 groups ( in&#xD;
      total 110patients in each group) to receive either Midodrine+Tolvaptan or tolvaptan+placebo&#xD;
      for 7 days followed by follow up for 1 month. These patients will be admitted to the hospital&#xD;
      from OPD or emergency.&#xD;
&#xD;
      In patients with cirrhosis with Patients with cirrhosis -there are two types of hyponatremia.&#xD;
      hyponatremia is due to important losses of extracellular fluid, most commonly from the&#xD;
      kidneys (because of overdiuresis due to treatment with excessive doses of diuretics) or from&#xD;
      the gastrointestinal tract( hypovolemic hyponatremia) hyponatremia develops in the setting of&#xD;
      expanded extracellular fluid volume and plasma volume with ascites and edema.This condition&#xD;
      is known as hypervolemic or dilutional hyponatremia.A marked impairment of renal solute-free&#xD;
      water excretion, resulting in disproportionate renal retention of water with respect to&#xD;
      sodium retention.In SALT trail showed that tolvaptan showed improvement in Na+ concentration&#xD;
      from baseline at 4 ,30 day. It acts on by increasing free water generation by blocking ADH&#xD;
      receptors in distal convoluted tubule. A study by Patel et al in 2017 showed that midodrine&#xD;
      also increasing the Na+ by increasing the free water delivery to distal convoluted tubules(in&#xD;
      cirrhosis usually there is less water delivery to distal convoluted tubules in view of less&#xD;
      GFR).Till now there is no study has been done as combination of midodrine and tolvaptan&#xD;
      whether superior to tolvaptan alone or not .So our aim is to study combination of midodrine&#xD;
      and tolvaptan verses tolvaptan alone in patients with hyponatremia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Aim and Objective -&#xD;
&#xD;
           AIM:&#xD;
&#xD;
           • To study effect of the combination of Midodrine and Tolvaptan versus Tolvaptan alone&#xD;
           in patients with severe hyponatremia in cirrhosis.&#xD;
&#xD;
           PRIMARY Objective :&#xD;
&#xD;
           • To study the Improvement in sodium concentration from base line to target level 125&#xD;
           meq/L in patients with hyponatremia ( Time frame-1 week) SECONDARY Objective :- To study&#xD;
           the&#xD;
&#xD;
           1 The change in Na+ concentration at D2,D4,D5. 2) Maintenance of Na concentration at&#xD;
           d14, d30 3) Improvement in Na+ concentration from base line to 130 meq/l at day 7 4)&#xD;
           Improvement in ascites at day 7,30 5) Development of AKI, HE [ 1 week,2 weeks,D30] 6)&#xD;
           Osmolality changes, urine volume,urinay Na + excretion at D3,D5,D7,D14 D30 7) Mean&#xD;
           arterial pressure at D1,D7,D14,D30. 8) RBC water and Na concentration in RBC cell at day&#xD;
           7, 30 9) Change in body weight at day 7, 30 10) The urine metabolomics&#xD;
&#xD;
        2. Methodology:&#xD;
&#xD;
             -  Study Definitions:&#xD;
&#xD;
      Hyponatermia as&#xD;
&#xD;
      Mild-126-130 Moderate-121-125 Severe-&lt;120 Acute-&lt;48 hours Chronic &gt;48 hours - alukal et al&#xD;
      2020 Symptomatic-presence of symptoms Asymptomatic-no symptoms&#xD;
&#xD;
      Study population -All the patients of cirrhosis of liver patients visiting to ILBS and&#xD;
      diagnosed to have hyponatremia Study design - Open label Placebo RCT&#xD;
&#xD;
      Assuming that the response rate is 30% in tolvaptan group and 50% in midodrine +tolvaptan&#xD;
      group Alpha Error-5%,power 80% we need to enroll 200 cases, 100 each group.Further assuming&#xD;
      10% drop rate, 220 cases-110 in each arm(Allocated each group block randomization method,&#xD;
      block size-10)&#xD;
&#xD;
      At baseline, a complete history with clinical and physical examination, a record of&#xD;
      demographic profile, standard of care biochemical investigations would be done. All included&#xD;
      patients will be evaluated with -&#xD;
&#xD;
        -  Etiology of cirrhosis&#xD;
&#xD;
        -  Upper GI endoscopy&#xD;
&#xD;
        -  Haemogram (including reticulocyte count)&#xD;
&#xD;
        -  Liver function tests,Renal function tests&#xD;
&#xD;
        -  CBC/LFT/KFT/ELECTOLYTES/URINENa,URINEOsmolality,Sosmolality,thyroidprofile,S Cortisol,S&#xD;
           ADH,RBC water,RBC Na&#xD;
&#xD;
        -  UGIE endoscopy,Usg Abdomen/IVC and 2D echo,cardichaemodynamics,PRO BNP,PRA, Renal&#xD;
           resistivity index&#xD;
&#xD;
        -  USG abdomen with Doppler study&#xD;
&#xD;
        -  Fibroscan&#xD;
&#xD;
        -  Child-Pugh score , MELD The patients will be managed according to randomization.&#xD;
           Subsequently, patients would be assessed clinically each day at the baseline and&#xD;
           post-treatment at every day for 1 month.&#xD;
&#xD;
      ADVERSE EFFECTS Thirst Dry mouth Hypernatremia Renal dysfunction Abdomnal pain&#xD;
      Nasea/Vomitting Muscle cramp&#xD;
&#xD;
      DURATION:&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Na+ to 125meq/L</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Na + (120 -125 meq/L)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Na + (120 -125 meq/L)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum osmolality</measure>
    <time_frame>0,1day,3day,1week ,2 week,1 month</time_frame>
    <description>Serum osmolality normal range is 285 to 295 millimol/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine volume</measure>
    <time_frame>0,1day,3day,1week ,2 week,1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinay Na + excretion in body</measure>
    <time_frame>0,1day,3day,1week ,2 week,1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical complications(AKI,HE) in patients with hyponatremia</measure>
    <time_frame>1 week,1month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of AKI</measure>
    <time_frame>7 day</time_frame>
    <description>Changes is serum creatine level more than 0.3 within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to achieve sodium concentration to 125 meq/L</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Na+ concentration from base line to 130 meq/l</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial pressure</measure>
    <time_frame>Day 1,7,14, and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sodium concentration in RBC cell</measure>
    <time_frame>Day 7</time_frame>
    <description>It is measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sodium concentration in RBC cell</measure>
    <time_frame>Day 30</time_frame>
    <description>It is measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC water concentration in RBC cell</measure>
    <time_frame>Day 7</time_frame>
    <description>It is measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC water concentration in RBC cell</measure>
    <time_frame>Day 30</time_frame>
    <description>It is measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in ascites</measure>
    <time_frame>Day 30</time_frame>
    <description>I t will be measured by ultrasound abdomen and graded as Grade 1 (Mild) , Grade 2 (moderate) &amp; Grade 3 (massisve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of sodium concentration</measure>
    <time_frame>Day 14 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Day 7</time_frame>
    <description>It is measured by kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Day 30</time_frame>
    <description>It is measured by kilograms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Tolvaptan with Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan with Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan Tablets</intervention_name>
    <description>• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg</description>
    <arm_group_label>Tolvaptan with Midodrine</arm_group_label>
    <arm_group_label>Tolvaptan with Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine Oral Tablet</intervention_name>
    <description>• Midodrine 5 mg at &quot;0&quot; hours and then 5 mg every 8 hours to maintain Target MAP-80</description>
    <arm_group_label>Tolvaptan with Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Midodrine</description>
    <arm_group_label>Tolvaptan with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Child B/C cirrhosis&#xD;
&#xD;
          2. Hyponatremia( severe)&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
          4. Age-18-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AKI(1.5mg/dl)&#xD;
&#xD;
          2. Sepsis&#xD;
&#xD;
          3. Underlyig CKD&#xD;
&#xD;
          4. High risk varices&#xD;
&#xD;
          5. Recent Bleed in 2 weeks&#xD;
&#xD;
          6. Acute Symptomatic hyponatremia&#xD;
&#xD;
          7. SIADH&#xD;
&#xD;
          8. Hypothyroidism&#xD;
&#xD;
          9. Severe cardiopulmonary disease&#xD;
&#xD;
         10. Cerebrovascular accident&#xD;
&#xD;
         11. Multiple strokes;&#xD;
&#xD;
         12. Pseudohyponatremia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr G. Srinivasa Reddy, MD</last_name>
    <phone>01146300000</phone>
    <email>srinivasareddygolamari@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr G Srinivasa Reddy, MD</last_name>
      <phone>01146300000</phone>
      <email>srinivasareddygolamari@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

